Crystalline salts of psilocin are disclosed. The beneficial and therapeutic uses of the crystalline psilocin salts and of compositions containing the crystalline psilocin salts are also disclosed. The disclosure sets out methods of making and characterizing the crystalline psilocin salts.

Crystalline salts of psilocin are disclosed. The beneficial and therapeutic uses of the crystalline psilocin salts and of compositions containing the crystalline psilocin salts are also disclosed. The disclosure sets out methods of making and characterizing the crystalline psilocin salts.

A crystalline polymorphic form of psilocin is disclosed. The beneficial and therapeutic uses of the crystalline form and of compositions containing the crystalline form are also disclosed. The disclosure sets out methods of making and characterizing the crystalline form.

A crystalline polymorphic form of psilocin is disclosed. The beneficial and therapeutic uses of the crystalline form and of compositions containing the crystalline form are also disclosed. The disclosure sets out methods of making and characterizing the crystalline form.

The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. ##STR00001##

The present application relates to psilocin derivatives of Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. ##STR00001##

An automated method and system for determining the risk of developing a cancer in a subject, the method comprising preparing a tissue sample obtained from the subject for visually identifying at least one biological marker associated with the cancer, digitally scanning the prepared tissue sample, analyzing the scanned image of the tissue sample to identify regions of interest, quantifying at least one parameter associated with the marker, and executing an algorithm using the quantified parameter to calculate a risk score, wherein the risk score is representative of the risk of the individual developing the cancer.

An automated method and system for determining the risk of developing a cancer in a subject, the method comprising preparing a tissue sample obtained from the subject for visually identifying at least one biological marker associated with the cancer, digitally scanning the prepared tissue sample, analyzing the scanned image of the tissue sample to identify regions of interest, quantifying at least one parameter associated with the marker, and executing an algorithm using the quantified parameter to calculate a risk score, wherein the risk score is representative of the risk of the individual developing the cancer.

An intranasal composition comprising a dosage amount of 50-150 mg/ml 5-methoxy-N,N-dimethyltryptamine (5MeODMT) in a liquid medium, wherein the 5MeODMT is formulated as the chloride salt of 5MeODMT (5MeODMT hydrochloride) and wherein the 5MeODMT hydrochloride is crystalline and characterised by one or more of: peaks in an XRPD diffractogram; an endothermic event in a DSC thermograph; an onset of decomposition in a TGA thermograph; and a DVS isotherm profile.

An intranasal composition comprising a dosage amount of 50-150 mg/ml 5-methoxy-N,N-dimethyltryptamine (5MeODMT) in a liquid medium, wherein the 5MeODMT is formulated as the chloride salt of 5MeODMT (5MeODMT hydrochloride) and wherein the 5MeODMT hydrochloride is crystalline and characterised by one or more of: peaks in an XRPD diffractogram; an endothermic event in a DSC thermograph; an onset of decomposition in a TGA thermograph; and a DVS isotherm profile.